<code id='942895940D'></code><style id='942895940D'></style>
    • <acronym id='942895940D'></acronym>
      <center id='942895940D'><center id='942895940D'><tfoot id='942895940D'></tfoot></center><abbr id='942895940D'><dir id='942895940D'><tfoot id='942895940D'></tfoot><noframes id='942895940D'>

    • <optgroup id='942895940D'><strike id='942895940D'><sup id='942895940D'></sup></strike><code id='942895940D'></code></optgroup>
        1. <b id='942895940D'><label id='942895940D'><select id='942895940D'><dt id='942895940D'><span id='942895940D'></span></dt></select></label></b><u id='942895940D'></u>
          <i id='942895940D'><strike id='942895940D'><tt id='942895940D'><pre id='942895940D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:29369
          Joaquin Duato -- health policy coverage from STAT
          Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

          WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

          The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

          advertisement

          “​​The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

          BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM